Health Care
Children's Pulmonary Specialist
Front Office Ft Health Care
Old Pueblo Family Planning
Medical Assistant Trades/Construction
Dickens Quality Demolition
Project Manager Trades/Construction
ROR Constrution
Residential Framing Carpenters Education
Flowing Wells Schools
5th Grade Teacher Legal
LAW OFFICES OF DENNIS A ROSEN
LEGAL SECRETARY General
MG Properties
Maintenance Supervisor

CHICAGO — The federal government's new advice to doctors for helping smokers quit recommends the drug Chantix, which has recently been linked with depression and suicidal behavior.

The new guidelines mention the psychiatric risks, but also say the popular Pfizer Inc. drug is the most effective at helping people get off cigarettes. The guidelines mention other options, too, and highly recommend combining counseling and medication. But doctors are encouraged to talk to all smokers who want to quit about trying medication.

Consumer advocates cautioned that the safety picture on Chantix is incomplete because it's a relatively new drug, on the market just since 2006.

"It is somewhat better than other therapies; on the other hand, it appears to have more risk," said Dr. Sidney Wolfe of the watchdog group Public Citizen. "That part of the risk-benefit equation is missing, and it's changing rapidly."

Another issue with the quit-smoking guidelines, released this week by the U.S. Public Health Service, is the lead author's past connections with Pfizer.

Dr. Michael Fiore, an expert on smoking and health issues, was a consultant to the maker of Chantix. But he said he cut those ties in 2005.

The guidelines are based on an extensive review of scientific evidence, were reviewed by 90 independent experts and were endorsed by 60 public health entities, Fiore said, adding that his past financial ties to the drug industry had no influence.

The guideline authors analyzed 83 studies and found that Chantix helped 33 percent stay off tobacco for six months after quitting, compared with a nearly 14 percent abstinence rate for dummy pills.